Skip Navigation LinksHome > May 21, 2004 - Volume 18 - Issue 8 > Coaxing HIV-1 from resting CD4 T cells: histone deacetylase...
AIDS:
Basic Science

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

Ylisastigui, Loydaa; Archin, Nancie Ma; Lehrman, Gingera; Bosch, Ronald Jc; Margolis, David Ma,b

Free Access
Article Outline
Collapse Box

Author Information

From the aDepartment of Medicine, University of Texas Southwestern Medical Center and bNorth Texas Veterans Health Care Systems, Dallas, Texas and cHarvard School of Public Health, Boston, Massachusetts, USA.

Correspondence to Dr D. M. Margolis, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Y9-206a, Dallas, Texas 75390-9113, USA.

Received: 17 November 2003; revised: 27 January 2004; accepted: 16 February 2004.

Collapse Box

Abstract

Background: Histone deacetylase (HDAC), a host mediator of gene repression, inhibits HIV gene expression and virus production and may contribute to quiescence of HIV within resting CD4 T cells.

Objectives: To test the ability of valproic acid (VPA), an inhibitor of HDAC in clinical use, to induce expression of HIV from resting CD4 T cells.

Methods: Chromatin immunoprecipitation measured the capability of VPA to deacetylate the HIV promoter, a remodeling of chromatin linked to gene expression. The effect of VPA on resting CD4 T cell phenotype was measured by flow cytometric analysis, and its effect on de novo HIV infection of peripheral blood mononuclear cells was measured ex vivo. Outgrowth of HIV from resting CD4 T cells of aviremic, HIV-infected donors treated with highly active antiretroviral therapy was compared in limiting-dilution cultures after mitogen stimulation or exposure to VPA.

Results: VPA induced acetylation at the integrated HIV proviral promoter, but CD4 cells exposed to VPA did not become activated or more permissive for de novo HIV infection. VPA induced outgrowth of HIV from the resting CD4 cells of aviremic patients at concentrations achievable in vivo as frequently as did mitogen stimulation.

Conclusions: With advances in antiretroviral therapy, HIV infection might be cleared by intensive time-limited treatment coupled with practical strategies that disrupt latency without enhancing new infection. HDAC inhibitors are capable of inducing expression of quiescent provirus, without fully activating cells or enhancing de novo infection, and may be useful in future clinical protocols that seek to eradicate HIV infection.

Back to Top | Article Outline

Introduction

Suppressive antiretroviral therapy is often clinically successful, but eradication of HIV infection is an ideal therapeutic goal. One of the major obstacles to eradication of HIV infection is the persistent, quiescent infection of resting CD4 memory T cells [1]. Histone deacetylase (HDAC), a host mediator of gene inhibition, can inhibit HIV gene expression and virus production, and contributes to quiescence within resting cells harvested from HIV-positive patients [2–5].

Mechanisms that allow HIV to establish latency are unknown, but recent evidence suggests that modulation of histone architecture within the viral promoter participates in this process. The integrated HIV long terminal repeat (LTR) promoter requires remodeling to allow expression, and histone acetylation to respond to NF-kB activation. Its activation is augmented by HDAC inhibitors [6–12]. These observations imply a role for HDAC in the establishment or maintenance of quiescence. Local chromatin effects have long been thought to contribute to the durable suppression of HIV proviral expression, and latently infected cells recovered from a T lymphocyte cell line infected in vitro were recently found to contain HIV integrated in or close to alphoid repeat elements in heterochromatin [13,14].

HDAC1 is specifically recruited to the LTR at a domain adjacent to the transcriptional initiation site [2,3,15]. HDAC1 recruitment can deacetylate the adjacent nucleosome 1 (nuc 1) of the LTR and inhibits Tat activation, LTR expression, and viral production [4]. Recently, we have shown that novel small molecules that specifically block HDAC recruitment to the LTR allow outgrowth of latent HIV from resting CD4 T cells obtained from HIV-infected patients [5].

While no available experimental system recapitulates all aspects of quiescent HIV infection within primary CD4 T cells, studies of quiescent HIV infection have been performed ex vivo in resting CD4 lymphocytes isolated from HIV-infected volunteers [16–21]. HIV is expressed from these cells if activated by mitogens or T cell signaling cytokines.

We hypothesized that inhibition of HDAC activity would allow outgrowth of HIV from latently infected resting CD4 T cells. Valproic acid (VPA) has recently been demonstrated to be a direct inhibitor of HDAC, and this capability has been linked to the clinical effects of VPA [22]. VPA is in wide use and often given to HIV-infected patients to treat concomitant conditions. In early studies, HIV gene expression and virus production were increased in vitro in the presence of VPA [23,24]. Literature prior to the era of highly active antiretroviral therapy (HAART) advised against the use of VPA as it might increase plasma HIV RNA, although a small study recently observed no effect in the presence of HAART [25,26].

The present study examines the ability of the HDAC inhibitor VPA to induce acetylation at the integrated HIV LTR, the effect of VPA on de novo HIV infection, and the ability of VPA to induce expression of HIV from purified resting CD4 T cells obtained from HIV-positive donors.

Back to Top | Article Outline

Methods

Chromatin immunoprecipitation

J89 cells (2 × 106 cells) [27] were washed with phosphate-buffered saline (PBS) and incubated overnight at 37°C under 5% carbon dioxide in media containing 0.5% fetal bovine serum (FBS; Invitrogen, Carlsbad, California, USA). Cells were then washed and incubated for 2 h in media without serum and containing 400 nmol/l trichostatin A (Sigma, St Louis, Missouri, USA) or 1–5 mmol/l VPA (Sigma), or they were were untreated. FBS was then added to a final concentration of 20% and cells were incubated only for an additional 2 h to avoid the induction of secondary gene effects. Cells were washed with PBS, cross-linked with 1% formaldehyde, washed again, snap-frozen in an ethanol/dry-ice bath and stored at −80°C. Chromatin immunoprecipitation assays were carried out as described [4] with modifications as follows. Briefly, cells were thawed on ice and incubated with 200 μl lysis buffer (Upstate, Waltham, Massachusetts, USA) containing 40 μl protease inhibitor cocktail (Sigma) for 10 min at 4°C; 300 μl dilution buffer (Upstate) was added to the cell lysates, which were then sonicated to fragment chromatin to 500 to 1000 base pairs. After centrifugation of sonicated cell lysates, 60 μg soluble chromatin was incubated overnight with 5 μl anti-acetylhistone H4 (Upstate) or rabbit pre-immune immunoglobulin G (Sigma). Immunoprecipitates were incubated with 50 μl salmon sperm DNA/protein A agarose beads (Upstate) for 1 h at 4°C. Agarose beads were recovered by centrifugation and washed using buffers from the chromatin immunoprecipitation assay kit (Upstate) following the manufacturers’ instructions. Immunoprecipitated DNA was eluted with 500 ml elution buffer (1% sodium dodceyl sulfate plus 0.1 mol/l sodium bicarbonate). DNA was reverse cross-linked by incubation in a solution containing 19 mg proteinase K [polymerase chain reaction (PCR) grade; Boehringer Mannheim, Germany] at 65°C for 90 min. DNA was extracted in phenol/chloroform/isoamyl alcohol, precipitated in ethanol, washed and resuspended in 50 ml water.

Quantitative duplex PCR assay was performed to analyze the amount of DNA precipitated by specified antibodies in proportion to input DNA. The sequence of primers for the HIV-1 LTR promoter was LTR-109F (5′-TACAAGGGACTTTCCGCTGG-3′) and LTR+82R (5′-AGCTTTATTGAGGCTTAAGC-3′). PCR was carried over 32–34 cycles using 5 μl precipitated DNA in a 25 μl PCR reaction. PCR products were resolved by 8% polyacrylamide gel electrophoresis and visualized by ethidium bromide staining. PCR products were quantified by AlphaImager 2000 (Alpha Innotech Corp., San Leandro, California, USA).

Back to Top | Article Outline
Lymphocyte phenotyping

Resting cells from HIV-infected patients were phenotyped immediately after isolation. Peripheral blood mononuclear cells (PBMC) were incubated with 20 U/ml interleukin-2 (IL-2; Chiron, Emeryville, California, USA), 2 μg/ml phytohemaglutinin (PHA; Boehringer Mannheim, Indianapolis, Indiana, USA) plus IL-2, 0.2 mmol/l VPA plus IL-2, or 1.0 mmol/l VPA plus IL-2 for 72 h in conditions identical to those used for outgrowth assays and then phenotyped. PBMC or resting CD4 T cells were washed and labeled with a cocktail of monoclonal antibodies for 30 min at 4°C: HLA-DR–fluoroscein isothiocyanate (FITC), CD25–phycoerythrin (PE), CD69–PE, CD38–PE, Ki-67–FITC, CXCR4–PE, CCR5–FITC, CD3–peridinin–chlorophyll a complex protein, and CD4–allophycocyanin (Beckton Dickinson, San Jose, California, USA). Stained cells were washed in PBS containing 2% FBS and subjected to cytofluorimetric analysis performed on a FACSCalibur (Becton Dickinson) equipped with Cell Quest (Macintosh, Sunnyvale, California, USA) software. For the analysis, total lymphocytes were first identified and gated by forward and side scatter. Then, cells were additionally gated for CD4 expression. A total of 10 000 gated events were collected for each sample.

Back to Top | Article Outline
Peripheral blood mononuclear cell infections

PBMC obtained from HIV-seronegative donor buffy coats were treated with 20 U/ml IL-2, 2 μg/ml PHA plus IL-2, 0.2 mmol/l VPA plus IL-2, or 1.0 mmol/l VPA plus IL-2 for 3 days. PBMC (4 × 106 cells) were then infected for 12 h with HIVLAI (10 ng p24) in the presence of 5 μg/ml polybrene. PBMC were washed and fed with media and IL-2; samples for p24 enzyme-linked immunosorbent assay (ELISA) were taken daily, and media replaced.

Back to Top | Article Outline
Limiting dilution cultures of latently infected CD4 T cells from HIV-positive donors

To obtain a sufficient number of infected resting CD4 T cells, leukopheresis was performed for five stably treated, aviremic HIV-positive volunteers (plasma HIV-1 RNA < 50 copies /ml for more than 6 months; CD4 cell counts > 400 × 106 cells/l). Informed consent was obtained from all patients. Resting CD4 T cells were negatively selected from leukopheresis samples using magnetic bead elution. HIV outgrowth assays were performed as previously described [16] with the following modifications. Cells were maintained without IL-2 for 3–4 days in culture in the presence of 10 μmol/l L-731,988, an investigational integrase inhibitor [28], and a reverse transcriptase inhibitor to which the donor had not been exposed. L-731,988 at 10 μmol/l is reported to inhibit completely integration of HIV [27]. Efavirenz (gift of Bristol-Meyers Squibb) or abacavir (gift of Glaxo SmithKline) were used at 15 nmol/l and 4 μmol/l, respectively, concentrations 10 times above the median inhibitory concentration for wild-type HIV.

After this period of incubation, in limiting dilution format, 5.0–0.1 × 106 resting CD4 cells were (a) activated with 2 μg/ml PHA-L, 6 × 106 allogeneic irradiated PBMC from an HIV-seronegative donor, and 100 U/ml IL-2; (b) treated with 0.2–1.0 mmol/l VPA and 100 U/ml IL-2; or (c) cultured in 100 U/ml IL-2 alone. After 72 h, the cultures were expanded with the addition of 106 CD8-depleted seronegative donor PBMC. Cultures were fed with media and 20 U/ml IL-2, and supernatants harvested every 3–4 days. Additional CD8-depleted PBMC were added every 7 days; virus was detected by p24 antigen capture ELISA. Cultures were carried for up to 28 days.

Back to Top | Article Outline

Results

Valproic acid induced acetylation at the integrated HIV long terminal repeat

The nucleosome nuc 1 is positioned about the HIV LTR between +1 and +155 with respect to the transcription start site of HIV-1 LTR [6]. Studies have suggested that disruption of this nucleosome accompanies activation of transcription of the integrated LTR [6–10]. The exposure of cell lines containing a single HIV integrant to the potent HDAC inhibitor trichostatin A results in the displacement of HDAC1 from nuc 1 about the HIV LTR initiation region, in association with increased acetylation of histone H4 and increased LTR expression [4].

To confirm that VPA could induce chromatin remodeling via HDAC inhibition, it would be desirable to perform similar assays on resting CD4 T cells from HIV-infected individuals. However, this is not technically feasible because of the rarity of replication-competent integrated HIV and the frequency of non-integrated HIV DNA in cells obtained from HIV-positive patients. To document changes induced by VPA in histone H4 acetylation at nuc 1 in vivo, chromatin immunoprecipitation assays were performed in J89 T cell lines containing a single integrated HIV genome [27]. These T cell lines are a model of latency in which expression of integrated provirus can be induced by activation, and in which quiescence is reestablished when activating stimulus is withdrawn.

Using an antibody directed against acetylated histone H4, DNA fragments associated with acetylated histone H4 were precipitated from cell extracts. The precipitated HIV LTR DNA was quantified by PCR with primers spanning the nuc 1 region of LTR. Amplification of serial dilutions of DNA demonstrated that a twofold increase in density units of PCR product represented at least a fourfold increase in target DNA [4]. As chromatin immunoprecipitation is a qualitative assay of factor occupancy at a specific DNA sequence, any twofold increase in PCR product observed in these assay conditions represents a significant qualitative increase in occupancy. Cells were assayed after only a 4 h exposure to VPA, as longer periods of time might allow the observation of the chromatin remodeling events that occur during cell cycle progression or in response to the expression of other host genes. As shown in Fig. 1, exposure of cells to 1 mmol/l VPA for 2 h results in a significant increase in acetylated histone H4 at nuc 1.

Fig. 1
Fig. 1
Image Tools
Back to Top | Article Outline
Valproic acid induced outgrowth of HIV from the resting CD4 T cells of aviremic HIV-positive donors

A major latent reservoir of HIV infection resides in resting memory CD4 T cells, which harbor integrated, functional, but quiescent proviral HIV genomes. This reservoir can be detected, quantified, and studied by negative selection of resting CD4 T cells on the basis of surface markers, incubation of limiting dilutions of cells with an activator of T cell proliferation or signaling, and amplifying the resultant output virus by the addition of CD4 lymphoblasts from uninfected donors [16–21]. The selection of HIV-infected donors with prolonged suppression of viremia minimizes the potential for the outgrowth of actively replicating HIV in cultures of resting cells.

Lymphocytes were obtained by leukopheresis from five volunteers with CD4 cell counts ranging from 558 to 898 × 106 cell/l. Four of these subjects had been aviremic (< 50 copies/ml HIV-1 RNA) for 24–28 months; one was aviremic for significantly longer than 11 months but documentation of the last date of detectable HIV RNA was unavailable. More than 110 × 106 resting cells were studied in each of the four subjects; 52 × 106 resting cells were available for study in the fifth subject. In total, > 490 × 106 resting CD4 T cells were tested in 176 limiting-dilution cultures.

Because of the stringent conditions and the small numbers of latently infected cells, replication-competent HIV was only recovered in 39 of 176 cultures. However, exposure of resting CD4 cells to safe and clinically achievable concentrations of VPA resulted in outgrowth of HIV at a frequency comparable to that following full cell activation with PHA (Table 1). HIV was recovered in 21 cultures activated with PHA and 18 cultures exposed to VPA. Using a maximum likelihood method [29], the infectious units per 106 resting CD4 cells was calculated for each patient sample using the data from PHA stimulation or VPA exposure. Differences in this estimated value within each subject between PHA and VPA were not statistically significant.

Table 1
Table 1
Image Tools

Outgrowth was not consistently detected in the cultures containing the greatest numbers of patient resting cells, perhaps because of suboptimal viability of cells in high-input cultures. No virus was detected in negative control cultures with an equivalent range of input cells maintained in IL-2 for up to 30 days.

Back to Top | Article Outline
Valproic acid did not induce de novo infection or expression of activation markers

As the goal of induction of latent HIV expression would be to allow eradication of chronic viral infection, reagents used to induce viral outgrowth should not simultaneously increase the likelihood of de novo infection. Global inhibition of HDAC activity is reported to alter significantly the expression of only 2% of host genes [30].

Cell surface phenotype analysis and de novo infection in the presence of VPA was examined to explore the global effect of VPA on PBMC in relation to HIV-1 infection.

PBMC were pretreated with IL-2, PHA plus IL-2, or VPA plus IL-2 for 3 days. Pretreated PBMC were then infected with a CXCR4-tropic clone (HIVLAI) and p24 assayed over 2 weeks. Whereas VPA induced HIV expression from latently infected CD4 cells, infection of seronegative donor cells in the presence of 0.2–1 mmol/l VPA and IL-2 did not result in a change in production of HIV compared with cells cultured with IL-2 alone (Fig. 2). To eliminate the possibility that VPA exposure increased HIV entry and/or reverse transcription, despite the fact that it did not upregulate de novo productive infection, HIV DNA PCR was performed. Equivalent amounts of HIV DNA were detected in cells infected in the presence of VPA/IL-2 or IL-2, more than fourfold less than in PHA-activated cells (not shown). Findings using a CCR5-tropic viral clone (HIVBaL) were similar (not shown).

Fig. 2
Fig. 2
Image Tools

Expression of activation markers on the surface of lymphocytes was unaltered by VPA. Exposure of PBMC to up to 1 mmol/l VPA and 20 U/ml IL-2 did not significantly upregulate cell surface expression of CD38, CD69, CD25, or HLA-DR on CD3+CD4+ or CD3+CD8+ cells compared with cells cultured in 20U/ml IL-2 alone (Fig. 3).

Fig. 3
Fig. 3
Image Tools
Back to Top | Article Outline

Discussion

Even in the face of a highly potent antiviral immune response, a proportion of replication competent HIV escapes viral clearance and establishes quiescence within resting CD4 cells. Disease can be prevented by chronic suppressive antiviral therapy, but this is fraught with toxicities and costs, and it is threatened by the potential of HIV to develop drug resistance. Clearance of HIV infection should be a therapeutic goal, although it may be a difficult one. While advances in antiviral and immunotherapy may allow the termination of low-level viral replication in a variety of cellular compartments and reservoirs, HIV will remain a chronic viral infection unless there are therapeutic answers to persistent, latent infection of resting CD4 T cells. Selective induction of latent HIV would allow antiretroviral drugs and the antiviral immune response to access this residual HIV infection.

Several studies have shown that intensive antiretroviral therapy in combination with IL-2 or global T cell activators fails to eradicate HIV infection [31–36]. Modeling studies suggest that global T cell activation may induce viral replication and increase the number of susceptible uninfected target cells beyond the threshold that can be contained by antiretroviral therapy [37]. An alternative approach could use reagents that selectively activate quiescent proviral genomes but have limited effects on the host cell; this might allow outgrowth of latent HIV and avoid the pitfalls of global T cell activation.

Prostratin, a unique phorbol ester, and the human cytokine interleukin-7 have been reported to reactivate latent HIV [38–40]. These reagents, however, are not yet available for use in humans. As HDAC contributes to quiescence within the resting cells of HIV-positive patients [2–5], it was interesting to see if VPA, an HDAC inhibitor that is often given to HIV-infected patients for other conditions, could induce expression of latent HIV from their cells ex vivo.

VPA was surprisingly effective at inducing outgrowth of HIV from resting cells harvested from the peripheral blood, no less effective than activation with the mitogen PHA. Our findings differ from those of Brooks et al. [40], who found the more potent HDAC inhibitor trichostatin ineffective in inducing outgrowth of latent HIV. One possible explanation for this discrepancy is that more potent HDAC inhibition induces cellular toxicity or alters host gene expression in a way that prevents viral outgrowth ex vivo. We have found that latent HIV was only rarely recovered when cells were treated with 5 mmol/l VPA (data not shown). In addition, thymocytes are implanted and infected in the mouse model studied by Brooks et al., resulting in latently infected naive CD4 T cells. Latent HIV may occur less frequently within naive cells than in peripheral memory CD4 cells [41], and expression of provirus may be regulated differently in naive cells than in the memory cell populations we have studied.

It should be noted that CD4 lymphocytes were maintained ex vivo in these studies with IL-2. Although virus was not recovered in our culture conditions when cells were maintained with IL-2 alone, IL-2 in higher concentrations can itself induce viral replication [42]. A cooperative effect between VPA and IL-2 in allowing viral outgrowth cannot be ruled out.

We found that VPA induced outgrowth of HIV from the resting CD4 cells of aviremic patients exposed ex vivo to VPA concentrations achievable in vivo. When exposed to VPA, CD4 cells did not become activated or more permissive for viral replication. VPA is, therefore, a drug that may be used clinically to perturb the quiescent reservoir of HIV infection within resting CD4 T cells.

Current therapy is not yet potent enough to block all active HIV replication [43–47]. However, the clinical experience with VPA may make it possible to test the ability to deplete the latent reservoir in test-of-principal clinical experiments. If future advances in immunotherapeutics and antiretroviral chemotherapy can terminate viral replication, interventions that derepress the LTR and result in selective expression of the quiescent HIV may deplete the reservoir of persistent HIV infection and make it possible to eliminate HIV infection.

Back to Top | Article Outline

Acknowledgements

We thank H. Wise for primary study coordination, with assistance from M. B. Kvanli and D. Turner. We thank J. P. Kassirer, J. V. Garcia, R. Gaynor, and G. D. Miralles for advice and careful review.

Sponsorship: This and related work was supported by an amfAR award and N.I.H. grants (RO1-AI 45297 and UO1-AI46376) to D.M.M.

Back to Top | Article Outline

References

1. Pierson T, McArthur J, Siliciano RF. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol. 2000, 18:665–708.

2. Coull JJ, Romerio F, Sun JM, Volker JL, Galvin KM, Davie JR, et al. The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1. J Virol 2000, 74:6790–6799.

3. Coull JJ, He G, Melander C, Rucker V, Dervan PB, Margolis DM. Targeted derepression of the human immunodeficiency type 1 virus long terminal repeat by pyrrole-imidazole polyamides. J Virol 2002, 76:12349–12354.

4. He G, Margolis DM. Counter-regulation of chromatin acetylation and histone deacetylase occupancy at the integrated promoter of human immunodeficiency virus type 1 by the HIV-1 activator Tat and the HIV-1 repressor YY1. Mol Cell Biol 2002, 22:2965–2973.

5. Ylisastigui L, Coull JJ, Rucker V, Brodie SJ, Bosch RJ, Sodora D, et al. Polyamides reveal a role for repression in viral latency within HIV-infected donors’ resting CD4+ T cells. J Infect Dis 2004, in press.

6. Verdin E, Paras Jr P, van Lint C. Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation. EMBO J 1993, 12:3249–3259.

7. Pazin MJ, Sheridan PL, Cannon K, Cao Z, Keck JG, Kadonaga JT, et al. NF-κB-mediated chromatin reconfiguration and transcriptional activation of the HIV-1 enhancer in vitro. Genes Dev 1996, 10:37–49.

8. van Lint C, Emiliani S, Ott M, Verdin E. Transcriptional activation and chromatin remodeling of the HIV-1 promoter in response to histone acetylation EMBO J. 1996, 15:1112–1120.

9. Sheridan PL, Mayall TP, Verdin E, Jones KA. Histone acetyltrans-ferases regulate HIV-1 enhancer activity in vitro. Genes Dev 1997, 11:3327–3340.

10. El Kharroubi A, Piras G, Zensen R, Martin MA. Transcriptional activation of the integrated chromatin associated human immunodeficiency virus type 1 promoter. Mol Cell Biol 1998, 18:2535–2544.

11. Benkirane M, Chun RF, Xiao H, Ogryzko VV, Howard BH, Nakatani Y, et al. Activation of integrated provirus requires histone acetyltransferase. p300 and P/CAF are coactivators for HIV-1 Tat. J Biol Chem 1998; 273:24898–24905.

12. Quivy V, Adam E, Collette Y, Demonte D, Chariot A, Vanhulle C, et al. Synergistic activation of human immunodeficiency virus type 1 promoter activity by NF-κB and inhibitors of deacetylases: potential perspectives for the development of therapeutic strategies. J Virol 2002, 76:11091–11103.

13. Jordan A, Bisgrove D, Verdin E. HIV reproducibly establishes a latent infection after acute infection of T cells in vitro. EMBO J 2003, 22:1868–1877.

14. Winslow BJ, Pomerantz RJ, Bagasra O, Trono D. HIV-1 latency due to the site of proviral integration. Virology 1993, 196: 849–854.

15. Romerio F, Gabriel MN, Margolis DM. Repression of HIV-1 through the novel cooperation of the human factors YY1 and LSF. J Virol 1997, 71:9375–9382.

16. Chun T-W, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med 1995, 12:1284–1290.

17. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295–300.

18. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CI, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291–1295.

19. Chun T-W, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997, 94:13193–13197.

20. Chun T-W, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183–188.

21. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T. Nat Med 2003, 9: 727–728.

22. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001, 276:36734–36741.

23. Moog C, Kuntz-Simon G, Caussin-Schwemling C, Obert G. Sodium valproate, an anticonvulsant drug, stimulates human immunodeficiency virus type 1 replication independently of glutathione levels. J Gen Virol 1996, 77:1993–1999.

24. Witvrouw M, Schmidt J-C, van Romoortel B, Daelmans D, Este JA, Vandamme A-M, et al. Cell type-dependent effect of sodium valproate on human immunodeficiency virus type 1 replication in vitro. AIDS Res Hum Retroviruses 1997, 13:187–192.

25. Maggi JD, Halman MH. The effect of divalproex sodium on viral load: a retrospective review of HIV-positive patients with manic syndromes. Can J Psychiatry 2001, 46:359–362.

26. Jennings HR Romanelli F. The use of valproic acid in HIV-positive patients. Ann Pharmacother 1999, 33:1113–1116.

27. Kutsch O, Benveniste EN, Shaw GM, Levy DN. Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency. J Virol 2002, 76: 8776–8786.

28. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287:646–650.

29. Myers LE, McQuay LJ, Hollinger FB. Dilution assay statistics. J Clin Microbiol 1994, 32::732–739.

30. van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996, 5:245–253.

31. Chun TW, Engel D, Mizell SB, Hallahan CW, Fischette M, Park S, et al. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999, 5:651–655.

32. Prins JM, Jurriaans S, van Praag RM, Blaak H, van Rij R, Schellekens PT, et al. Immuno-activation with anti-CD3 and recombinant human IL-2 In HIV-1- infected patients on potent antiretroviral therapy. AIDS 1999, 13:2405–2410.

33. van Praag RM Prins JM, Roos MT, Schellekens PT, Ten Berge IJ, Yong SL, et al. OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 2001, 21:218–226.

34. Kulkosky J, Nunnari G, Otero M, Calarota S, Dornadula G, Zhang H, et al. Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy. J Infect Dis 2002, 186:1403–1411.

35. Stellbrink HJ, van Lunzen J, Westby M, O'Sullivan E, Schneider C, Adam A, et al. Effects of interleukin-2 plus highly active antiretroviral therapy on HIV-1 replication and proviral DNA (COSMIC trial). AIDS 2002, 16:1479–1487.

36. Dybul M, Hidalgo B, Chun TW, Belson M, Migueles SA, Justement JS, et al. Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection. J Infect Dis 2002, 185:61–68.

37. Fraser C, Fergeson, NM, Ghani AC, Prins JM, Lange JM, Goudsmit J, et al. Reduction of the HIV-1 infected T cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS 2002, 14:659–669.

38. Kulkosky J, Culnan DM, Roman J, Dornadula G, Schnell M, Boyd MR, et al. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001, 98:3006–3015.

39. Brooks DG, Hamer DH, Arlen PA, Gao L, Bristol G, Kitchen CM, et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003, 19:413–423.

40. Brooks DG, Arlen PA, Gao L, Kitchen CM, Zack JA. Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc Natl Acad Sci USA 2003, 100:12955–12960.

41. Shen A, Zink MC, Mankowski JL, Chadwick K, Margolick JB, Carruth LM, et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol 2003, 77:4938–4949.

42. Kinter AL, Poli G, Fox L, Hardy E, Fauci AS. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines. J Immunol 1995, 154:2448–2459.

43. Dornadula G, Zhang H, van Uitert B, Stern J, Livornese L Jr, Ingerman MJ, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999, 282:1627–1632.

44. Gunthard HF, Frost SD, Leigh-Brown AJ, Ignacio CC, Kee K, Perelson AS, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 1999, 73: 9404–9412.

45. Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, Kovacs JA. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 1999, 353:119–120.

46. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999, 340:1605–1613.

47. Ramratnam B, Mittler JE, Zhang L, Boden D, Hurley A, Fang F, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged antiretroviral therapy. Nat Med 2000, 6:82–85.

Cited By:

This article has been cited 67 time(s).

Expert Opinion on Biological Therapy
Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design
Chen, WZ; Ying, TL; Dimitrov, DS
Expert Opinion on Biological Therapy, 13(5): 657-671.
10.1517/14712598.2013.761969
CrossRef
Plos One
Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+Cell Infection
Archin, NM; Cheema, M; Parker, D; Wiegand, A; Bosch, RJ; Coffin, JM; Eron, J; Cohen, M; Margolis, DM
Plos One, 5(2): -.
ARTN e9390
CrossRef
Plos One
Resting Regulatory CD4 T Cells: A Site of HIV Persistence in Patients on Long-Term Effective Antiretroviral Therapy
Tran, TA; de Herve, MGD; Hendel-Chavez, H; Dembele, B; Le Nevot, E; Abbed, K; Pallier, C; Goujard, C; Gasnault, J; Delfraissy, JF; Balazuc, AM; Taoufik, Y
Plos One, 3(): -.
ARTN e3305
CrossRef
Journal of Virology
High-frequency epigenetic repression and silencing of retroviruses can be antagonized by histone deacetylase inhibitors and transcriptional activators, but uniform reactivation in cell clones is restricted by additional mechanisms
Katz, RA; Jack-Scott, E; Narezkina, A; Palagin, I; Boimel, P; Kulkosky, J; Nicolas, E; Greger, JG; Skalka, AM
Journal of Virology, 81(6): 2592-2604.
10.1128/JVI.01643-06
CrossRef
Journal of Infectious Diseases
Eliminating persistent HIV infection: Getting to the end of the rainbow
Margolis, DM; Archin, NM
Journal of Infectious Diseases, 195(): 1734-1736.
10.1086/518254
CrossRef
Embo Journal
CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency
Tyagi, M; Karn, J
Embo Journal, 26(): 4985-4995.
10.1038/sj.emboj.7601928
CrossRef
Future Microbiology
CCAAT/enhancer-binding proteins and the pathogenesis of retrovirus infection
Liu, Y; Nonnemacher, MR; Wigdahl, B
Future Microbiology, 4(3): 299-321.
10.2217/FMB.09.4
CrossRef
Journal of Virology
Mitogen-activated protein kinases regulate LSF occupancy at the human immunodeficiency virus type 1 promoter
Ylisastigui, L; Kaur, R; Johnson, H; Volker, J; He, GC; Hansen, U; Margolis, D
Journal of Virology, 79(): 5952-5962.

Journal of Infectious Diseases
Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells
Choudhary, SK; Archin, NM; Margolis, DM
Journal of Infectious Diseases, 197(8): 1162-1170.
10.1086/529525
CrossRef
Journal of Virology
A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression
Keedy, KS; Archin, NM; Gates, AT; Espeseth, A; Hazuda, DJ; Margolis, DM
Journal of Virology, 83(): 4749-4756.
10.1128/JVI.02585-08
CrossRef
Retrovirology
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies
Colin, L; Van Lint, C
Retrovirology, 6(): -.
ARTN 111
CrossRef
Journal of Virology
Establishment of HIV Latency in Primary CD4(+) Cells Is due to Epigenetic Transcriptional Silencing and P-TEFb Restriction
Tyagi, M; Pearson, RJ; Karn, J
Journal of Virology, 84(): 6425-6437.
10.1128/JVI.01519-09
CrossRef
Seizure-European Journal of Epilepsy
Frequency of seizures and epilepsy in neurological HIV-infected patients
Kellinghaus, C; Engbring, C; Kovac, S; Moddel, G; Boesebecka, F; Fischera, M; Anneken, K; Klonne, K; Reichelt, D; Evers, S; Husstedt, IW
Seizure-European Journal of Epilepsy, 17(1): 27-33.
10.1016/j.seizure.2007.05.017
CrossRef
Future Virology
Establishment and maintenance of HIV latency: model systems and opportunities for intervention
Marsden, MD; Zack, JA
Future Virology, 5(1): 97-109.
10.2217/FVL.09.70
CrossRef
Retrovirology
PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA
Invernizzi, CF; Xie, BD; Richard, S; Wainberg, MA
Retrovirology, 3(): -.
ARTN 93
CrossRef
Drug Discovery Today
Emerging host cell targets for hepatitis C therapy
He, YP; Duan, W; Tan, SL
Drug Discovery Today, 12(): 209-217.
10.1016/j.drudis.2007.01.009
CrossRef
Blood
Induction of HIV-1 latency and reactivation in primary memory CD4(+) T cells
Bosque, A; Planelles, V
Blood, 113(1): 58-65.
10.1182/blood-2008-07-168393
CrossRef
Nucleic Acids Research
COUP-TF interacting protein 2 represses the initial phase of HIV-1 gene transcription in human microglial cells
Marban, C; Redel, L; Suzanne, S; Van Lint, C; Lecestre, D; Chasserot-Golaz, S; Leid, M; Aunis, D; Schaeffer, E; Rohr, O
Nucleic Acids Research, 33(7): 2318-2331.
10.1093/nar/gki529
CrossRef
Retrovirology
Latency: the hidden HIV-1 challenge
Marcello, A
Retrovirology, 3(): -.
ARTN 7
CrossRef
Journal of Neurovirology
Valproic acid does not affect markers of human immunodeficiency virus disease progression
Ances, BM; Letendre, S; Buzzell, M; Marquie-Beck, J; Lazaretto, D; Marcotte, TD; Grant, I; Ellis, RJ
Journal of Neurovirology, 12(5): 403-406.
10.1080/13550280600981695
CrossRef
Journal of Virology
Identification of cellular proteins that maintain retroviral epigenetic silencing: Evidence for an antiviral response
Poleshko, A; Palagin, I; Zhang, R; Boimel, P; Castagna, C; Adams, PD; Skalka, AM; Katz, RA
Journal of Virology, 82(5): 2313-2323.
10.1128/JVI.01882-07
CrossRef
Journal of Infectious Diseases
Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors
Ylisastigui, L; Coull, JJ; Rucker, VC; Melander, C; Bosch, RJ; Brodie, SJ; Corey, L; Sodora, DL; Dervan, PB; Margolis, DM
Journal of Infectious Diseases, 190(8): 1429-1437.

Future Virology
HIV latency: present knowledge and future directions
Contreras, X; Lenasi, T; Peterlin, BM
Future Virology, 1(6): 733-745.
10.2217/17460794.1.6.733
CrossRef
Journal of Theoretical Biology
Modeling HIV persistence, the latent reservoir, and viral blips
Rong, LB; Perelson, AS
Journal of Theoretical Biology, 260(2): 308-331.
10.1016/j.jtbi.2009.06.011
CrossRef
Current Hiv Research
HAART-persistent HIV-1 latent reservoirs: Their origin, mechanisms of stability and potential strategies for eradication
Kulkosky, J; Bray, S
Current Hiv Research, 4(2): 199-208.

Current Pharmaceutical Design
Chromatin modifications (acetylation/deacetylation/methylation) as new targets for HIV therapy
Varier, RA; Kundu, TK
Current Pharmaceutical Design, 12(): 1975-1993.

Genome Biology
Attacking pathogens through their hosts
Kellam, P
Genome Biology, 7(1): -.
ARTN 201
CrossRef
Annual Review of Medicine
Hide-and-seek: The challenge of viral persistence in HIV-1 infection
Geeraert, L; Kraus, G; Pomerantz, RJ
Annual Review of Medicine, 59(): 487-501.
10.1146/annurev.med.59.062806.123001
CrossRef
Lancet
HIV/AIDS epidemiology, pathogenesis, prevention, and treatment
Simon, V; Ho, DD; Karim, QA
Lancet, 368(): 489-504.

Hiv Clinical Trials
HIV Pharmacology: Barriers to the eradication of HIV from the CNS
Mcgee, B; Smith, N; Aweeka, F
Hiv Clinical Trials, 7(3): 142-153.

Amino Acids
Isoform-specific determinants in the HP1 binding to histone 3: insights from molecular simulations
Machado, MR; Dans, PD; Pantano, S
Amino Acids, 38(5): 1571-1581.
10.1007/s00726-009-0371-3
CrossRef
Epilepsies
Epilepsy seizures linked to HIV infection in Africa
Tegueu, CK; Maiga, Y
Epilepsies, 22(2): 134-142.

Journal of Virology
Epigenetic Silencing of Human Immunodeficiency Virus (HIV) Transcription by Formation of Restrictive Chromatin Structures at the Viral Long Terminal Repeat Drives the Progressive Entry of HIV into Latency
Pearson, R; Kim, YK; Hokello, J; Lassen, K; Friedman, J; Tyagi, M; Karn, J
Journal of Virology, 82(): 12291-12303.
10.1128/JVI.01383-08
CrossRef
Antimicrobial Agents and Chemotherapy
Human immunodeficiency virus type 1 latency model for high-throughput screening
Micheva-Viteva, S; Pacchia, AL; Ron, Y; Peltz, SW; Dougherty, JP
Antimicrobial Agents and Chemotherapy, 49(): 5185-5188.
10.1128/AAC.49.12.5185-5188.2005
CrossRef
Embo Journal
NF-kappa B p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation
Williams, SA; Chen, LF; Kwon, H; Ruiz-Jarabo, CM; Verdin, E; Greene, WC
Embo Journal, 25(1): 139-149.
10.1038/sj.emboj.7600900
CrossRef
Journal of Virology
Hexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces tat-independent HIV-1 expression but blunts cell activation
Klichko, V; Archin, N; Kaur, R; Lehrman, G; Margolis, D
Journal of Virology, 80(9): 4570-4579.
10.1128/JVI.80.9.4570-4579.2006
CrossRef
Current Pharmaceutical Design
The pharmaceutical potential of histone deacetylase inhibitors
Elaut, G; Rogiers, V; Vanhaecke, T
Current Pharmaceutical Design, 13(): 2584-2620.

Plos One
Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection
Reuse, S; Calao, M; Kabeya, K; Guiguen, A; Gatot, JS; Quivy, V; Vanhulle, C; Lamine, A; Vaira, D; Demonte, D; Martinelli, V; Veithen, E; Cherrier, T; Avettand, V; Poutrel, S; Piette, J; de Launoit, Y; Moutschen, M; Burny, A; Rouzioux, C; De Wit, S; Herbein, G; Rohr, O; Collette, Y; Lambotte, O; Clumeck, N; Van Lint, C
Plos One, 4(6): -.
ARTN e6093
CrossRef
Expert Reviews in Molecular Medicine
Pharmaceutical approaches to eradication of persistent HIV infection
Bowman, MC; Archin, NM; Margolis, DM
Expert Reviews in Molecular Medicine, 11(): -.
ARTN e6
CrossRef
Antiviral Research
StpC-based gene therapy targeting latent reservoirs of HIV-1
Turner, LS; Tsygankov, AY; Henderson, EE
Antiviral Research, 72(3): 233-241.
10.1016/j.antiviral.2006.06.010
CrossRef
Biochemical Pharmacology
HDAC inhibitors: Clinical update and mechanism-based potential
Glaser, KB
Biochemical Pharmacology, 74(5): 659-671.
10.1016/j.bcp.2007.04.007
CrossRef
AIDS
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir
Sagot-Lerolle, N; Lamine, A; Chaix, ML; Boufassa, F; Aboulker, JP; Costagliola, D; Goujard, C; Paller, C; Delfraissy, JF; Lambotte, O
AIDS, 22(): 1125-1129.

AIDS
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells
Archin, NM; Eron, JJ; Palmer, S; Hartmann-Duff, A; Martinson, JA; Wiegand, A; Bandarenko, N; Schmitz, JL; Bosch, RJ; Landay, AL; Coffin, JM; Margolis, DM
AIDS, 22(): 1131-1135.

Neurologic Clinics
Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: Toward rational targeted therapy
Oh, U; Jacobson, S
Neurologic Clinics, 26(3): 781-+.
10.1016/j.ncl.2008.03.008
CrossRef
Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms
Chromatin dynamics associated with HIV-1 Tat-activated transcription
Easley, R; Van Duyne, R; Coley, W; Guendel, I; Dadgar, S; Kehn-Hall, K; Kashanchi, F
Biochimica Et Biophysica Acta-Gene Regulatory Mechanisms, 1799(): 275-285.
10.1016/j.bbagrm.2009.08.008
CrossRef
Molecular Pharmacology
Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3 beta inhibition, and viral replication: A screening approach for new bipolar disorder drugs derived from the valproic acid core structure
Eickholt, BJ; Towers, GJ; Ryves, WJ; Eikel, D; Adley, K; Ylinen, LMJ; Chadborn, NH; Harwood, AJ; Nau, H; Williams, RSB
Molecular Pharmacology, 67(5): 1426-1433.
10.1124/mol.104.009308
CrossRef
Lancet
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study
Lehrman, G; Hogue, IB; Palmer, S; Jennings, C; Spina, CA; Wiegand, A; Landay, AL; Coombs, RW; Richman, DD; Mellors, JW; Coffin, JM; Bosch, RJ; Margolis, DM
Lancet, 366(): 549-555.

Journal of Infectious Diseases
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid
Siliciano, JD; Lai, J; Callender, M; Pitt, E; Zhang, H; Margolick, JB; Gallant, JE; Cofrancesco, J; Moore, RD; Gange, SJ; Siliciano, RF
Journal of Infectious Diseases, 195(6): 833-836.
10.1086/511823
CrossRef
Clinical and Experimental Rheumatology
HIV/AIDS: epidemic update, new treatment strategies and impact on autoimmunity
Croce, F; Piconi, S; Atzeni, F; Sarzi-Puttini, P; Galli, M; Clerici, M
Clinical and Experimental Rheumatology, 26(1): S48-S52.

Lancet
Valproic acid: a potential role in treating latent HIV infection
Routy, JP
Lancet, 366(): 523-524.

Nature Reviews Microbiology
Chromatin control of herpes simplex virus lytic and latent infection
Knipe, DM; Cliffe, A
Nature Reviews Microbiology, 6(3): 211-221.
10.1038/nrmicro1794
CrossRef
AIDS Research and Human Retroviruses
Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid
Archin, NM; Espeseth, A; Parker, D; Cheema, M; Hazuda, D; Margolis, DM
AIDS Research and Human Retroviruses, 25(2): 207-212.
10.1089/aid.2008.0191
CrossRef
AIDS Research and Human Retroviruses
Short Communication: Activation of Latent HIV Type 1 Gene Expression by Suberoylanilide Hydroxamic Acid (SAHA), an HDAC Inhibitor Approved for Use to Treat Cutaneous T Cell Lymphoma
Edelstein, LC; Micheva-Viteva, S; Phelan, BD; Dougherty, JP
AIDS Research and Human Retroviruses, 25(9): 883-887.
10.1089/aid.2008.0294
CrossRef
Antiviral Research
HIV reservoirs, latency, and reactivation: Prospects for eradication
Dahl, V; Josefsson, L; Palmer, S
Antiviral Research, 85(1): 286-294.
10.1016/j.antiviral.2009.09.016
CrossRef
Bioessays
From reactivation of latent HIV-1 to elimination of the latent reservoir: The presence of multiple barriers to viral eradication
Shan, L; Siliciano, RF
Bioessays, 35(6): 544-552.
10.1002/bies.201200170
CrossRef
Drug Discovery Today
Targeting HIV latency: pharmacologic strategies toward eradication
Xing, SF; Siliciano, RF
Drug Discovery Today, 18(): 541-551.
10.1016/j.drudis.2012.12.008
CrossRef
Journal of General Virology
Recent developments in human immunodeficiency virus-1 latency research
Chan, CN; Dietrich, I; Hosie, MJ; Willett, BJ
Journal of General Virology, 94(): 917-932.
10.1099/vir.0.049296-0
CrossRef
Current Hiv Research
Histone Deacetylase Inhibitor MC1293 Induces Latent HIV-1 Reactivation by Histone Modification In Vitro Latency Cell Lines
Qu, XY; Ying, H; Wang, XH; Kong, CJ; Zhou, X; Wang, PF; Zhu, HZ
Current Hiv Research, 11(1): 24-29.

Viruses-Basel
Lost in Transcription: Molecular Mechanisms that Control HIV Latency
Taube, R; Peterlin, BM
Viruses-Basel, 5(3): 902-U157.
10.3390/v5030902
CrossRef
Plos Pathogens
Phosphorylation of CDK9 at Ser175 Enhances HIV Transcription and Is a Marker of Activated P-TEFb in CD4(+) T Lymphocytes
Mbonye, UR; Gokulrangan, G; Datt, M; Dobrowolski, C; Cooper, M; Chance, MR; Karn, J
Plos Pathogens, 9(5): -.
ARTN e1003338
CrossRef
Journal of Virology
Targeting I kappa B Proteins for HIV Latency Activation: the Role of Individual I kappa B and NF-kappa B Proteins
Fernandez, G; Zaikos, TD; Khan, SZ; Jacobi, AM; Behlke, MA; Zeichner, SL
Journal of Virology, 87(7): 3966-3978.
10.1128/JVI.03251-12
CrossRef
Drugs of the Future
The Potential Role of Hdac Inhibitors in De-Silencing Latent Hiv Virus
Ververis, K; Karagiannis, TC
Drugs of the Future, 38(8): 575-583.
10.1358/dof.2013.38.8.1995769
CrossRef
Journal of Virology
An AP-1 Binding Site in the Enhancer/Core Element of the HIV-1 Promoter Controls the Ability of HIV-1 To Establish Latent Infection
Duverger, A; Wolschendorf, F; Zhang, MC; Wagner, F; Hatcher, B; Jones, J; Cron, RQ; van der Sluis, RM; Jeeninga, RE; Berkhout, B; Kutsch, O
Journal of Virology, 87(4): 2264-2277.
10.1128/JVI.01594-12
CrossRef
Retrovirology
Feline immunodeficiency virus latency
McDonnel, SJ; Sparger, EE; Murphy, BG
Retrovirology, 10(): -.
ARTN 69
CrossRef
AIDS
The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells
Shehu-Xhilaga, M; Rhodes, D; Wightman, F; Liu, HB; Solomon, A; Saleh, S; Dear, AE; Cameron, PU; Lewin, SR
AIDS, 23(15): 2047-2050.
10.1097/QAD.0b013e328330342c
PDF (9283) | CrossRef
AIDS
Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors
Archin, NM; Keedy, KS; Espeseth, A; Dang, H; Hazuda, DJ; Margolis, DM
AIDS, 23(14): 1799-1806.
10.1097/QAD.0b013e32832ec1dc
PDF (457) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
The Histone Deacetylase Inhibitor ITF2357 Decreases Surface CXCR4 and CCR5 Expression on CD4+ T-Cells and Monocytes and is Superior to Valproic Acid for Latent HIV-1 Expression in Vitro
Matalon, S; Palmer, BE; Nold, MF; Furlan, A; Kassu, A; Fossati, G; Mascagni, P; Dinarello, CA
JAIDS Journal of Acquired Immune Deficiency Syndromes, 54(1): 1-9.
10.1097/QAI.0b013e3181d3dca3
PDF (409) | CrossRef
Back to Top | Article Outline
Keywords:

latency; histone deacetylase; resting CD4 T cells

© 2004 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.